Furthermore, Jang et al. found that PSD specifically suppresses phosphorylation of c-Met and its downstream Akt signaling, effectively restraining the growth of gefitinib-resistant non-small cell lung cancer harboring c-Met amplification [19]. Here, MET is linked to non-small cell lung carcinoma.